CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
How to tell if tooth pain is caused by a sinus infection
November 12, 2024
Sinus infections strike more than 30 million Americans each year. Uncomfortable symptoms include nasal congestion, facial pressure and headaches. Tooth pain actually could be a sign of a sinus infection, too. Experts explain the connection.
Fluency Friday creates supportive environment for people who...
November 12, 2024
Children and teens from throughout the Cincinnati region gathered for Fluency Friday, a one-day workshop for those who stutter to connect while also giving their parents and caregivers a chance to learn from experts on stuttering, Local 12 reported.
Women, men undergoing kidney dialysis face different heart risks
November 12, 2024
Women have a higher risk of heart failure and stroke than men while undergoing dialysis for kidney failure, a study from the University of Cincinnati shows. However, women also have a lower overall risk of dying than men, researchers found.